Intellinetics heads into its May 14 earnings call with a dramatically lighter short position — but a cluster of insider selling and a leadership transition still hanging in the air.
Short interest has collapsed over the past month, falling more than 50% from mid-April highs to just 0.02% of the free float by April 28. That is not a story about short sellers capitulating under pressure; it is a story about a tiny position that was never particularly large getting even smaller. The move is notable in its speed — from roughly 1,845 thousand shares estimated short in early-to-mid April to around 874 thousand by April 28 — but at these levels the short book carries no meaningful squeeze risk. Cost to borrow is running at 5.8%, down 10% on the week and gradually easing from a January high of around 9%. Borrow availability, while not at the extremes seen when utilization touched 35.6% at its 52-week peak, has loosened considerably — current utilization is just 1.5%, meaning the lending pool is far from stressed. The ORTEX short score sits at 28.8, well below the sector median, reinforcing the picture of a disengaged short community.
The more interesting angle is insider activity. Both the CEO and CFO filed sales in early April. CEO Matthew Chretien sold a combined 3,510 shares across two transactions on April 8 at prices between $7.25 and $7.50. CFO Joseph Spain sold 843 shares on the same day. These follow a larger award-and-sell pattern from April 1, where a CEO-level grant of 36,131 shares was accompanied by a same-day sale of 12,403 shares at $7.45 — a routine post-vesting disposal rather than a directional bet, but worth noting given the company is mid-transition. Earlier sales from outgoing CEO James DeSocio and Acting Chairman Michael Taglich at prices above $11 serve as a reminder that current holders acquired or sold at materially higher levels.
Ownership is concentrated and insider-heavy. The top two holders — Michael and Robert Taglich — together control more than 26% of shares outstanding, though both trimmed positions in October 2025. Bard Associates added meaningfully in Q4 2025, picking up around 113,000 shares. Vanguard and BlackRock hold token positions, underscoring that this remains a micro-cap with limited institutional float. The holder count of just 18 institutions reflects the stock's niche appeal.
The March 30 full-year 2025 results offer the most recent fundamental signal. Intellinetics beat the EPS estimate by $0.05 — reporting a loss of $0.05 against a consensus of -$0.10 — but missed the revenue line, bringing in $4.32 million against an expected $4.46 million. The stock gained roughly 2.8% the day after the print and extended that to nearly 10% over the following week. The accompanying earnings call highlighted a sharpening go-to-market focus and a SaaS growth target amid improving margins, alongside a leadership transition — context that appears to have kept buyers modestly engaged despite the revenue miss.
The analyst price target of $14.50 on file is from August 2025, placing it well above the current price of $7.09. Given the staleness of that data and the significant change in the stock's trading level since then, that target should not be read as current Street consensus. No recent analyst changes are on record.
The May 14 event will be the first quarterly print under the new strategic direction outlined in March — the key question is whether SaaS momentum has translated into any revenue inflection, or whether the miss on full-year revenue foreshadowed a more persistent headwind.
See the live data behind this article on ORTEX.
Open INLX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
